SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-009851
Filing Date
2022-01-14
Accepted
2022-01-14 16:05:55
Documents
14
Period of Report
2022-01-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d232708d8k.htm   iXBRL 8-K 28813
2 EX-99.1 d232708dex991.htm EX-99.1 8342
6 GRAPHIC g232708g0114204834216.jpg GRAPHIC 4040
  Complete submission text file 0001193125-22-009851.txt   170155

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vnda-20220113.xsd EX-101.SCH 2928
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vnda-20220113_lab.xml EX-101.LAB 18139
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vnda-20220113_pre.xml EX-101.PRE 11432
8 EXTRACTED XBRL INSTANCE DOCUMENT d232708d8k_htm.xml XML 3372
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34186 | Film No.: 22531930
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences